Crossmark

Terapia con linfocitos T con receptor de antígeno quimérico (CAR-T) en pacientes con linfoma de célula B agresivo. Perspectiva actual tras una década de tratamiento

Crossref DOI link: https://doi.org/10.1016/j.medcli.2021.10.005

Published Print: 2022-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Catalá, Eva

Iacoboni, Gloria

Barba, Pere
Funding

Funding for this research was provided by:

Fundación Científica de la Asociación Española Contra el Cáncer

Instituto de Salud Carlos III
License Information

Text and Data Mining valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01
More Information

This article is maintained by: Elsevier

Article Title: Terapia con linfocitos T con receptor de antígeno quimérico (CAR-T) en pacientes con linfoma de célula B agresivo. Perspectiva actual tras una década de tratamiento

Journal Title: Medicina Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcli.2021.10.005

Content Type: article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.

Document is current

Any future updates will be listed below